Form 4: Director Novak Acquires KTTA Stock Options

Pasithea Therapeutics Director Alfred J. Novak was granted 42,913 stock options with an exercise price of $0.715, vesting over one year.

Summary

• Alfred J. Novak, a Director and 10% Owner of Pasithea Therapeutics Corp. (KTTA), was granted 42,913 stock options.
• The options have an exercise price of $0.715 per share.
• The grant date for these options was October 24, 2025.
• The options expire on October 23, 2035.
• The underlying securities are 42,913 shares of Pasithea Therapeutics Corp. common stock.
• The options will vest in full on the one-year anniversary of the grant date (October 24, 2026), contingent on Novak remaining a director.
• Full vesting will also occur upon a Change in Control as defined in the company's 2023 Stock Incentive Plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, indicating alignment of interests and a commitment to long-term value creation. It's a routine compensation event, not indicative of extraordinary performance, hence a neutral-to-positive score.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The vesting schedule encourages continued service and commitment from the director.

Negatives

• No immediate cash inflow for the director, as these are options, not shares.
• The value of the options is dependent on the future stock price exceeding the exercise price.

Risks

• The value of the options is subject to market fluctuations and the company's performance.
• If the stock price does not exceed the exercise price, the options may expire worthless.
• The director must remain with the company for one year for the options to vest, introducing a retention risk.

Future Outlook

The grant of stock options with a one-year vesting period suggests an expectation of continued service from the director and a belief in the company's future growth potential to make the options valuable.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, particularly for companies like Pasithea Therapeutics (KTTA), which may be in growth or development phases. This practice aims to align leadership incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a standard practice across many industries, including biotech, to incentivize performance and retention.
• The vesting schedule (one-year cliff vesting) is a common approach, though multi-year graded vesting is also prevalent in the industry.
• The exercise price being at or above the market price on the grant date is standard for incentive stock options, aligning with typical industry compensation structures.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution if options are exercised, but also potential for increased director alignment and motivation.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• The options will vest on October 24, 2026, assuming the director remains with the company.
• The director may choose to exercise the options at any point between vesting and the expiration date, subject to company policy.

Key Dates

Recommendation

This Form 4 reports a routine stock option grant to a director, which is a standard compensation practice. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily indicates continued director involvement and alignment of interests.

Keywords

Pasithea Therapeutics, KTTA, Stock Options, Director Compensation, SEC Form 4, Insider Trading, Equity Grant, Alfred J. Novak, Corporate Governance